Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Erbitux
Pharma
Merck KGaA tweaks 2025 forecast as geopolitical concerns mount
Citing tariff threats, Merck KGaA has lowered its sales guidance for its life science arm, which offers various services and materials for partners.
Fraiser Kansteiner
May 15, 2025 1:20pm
Merck KGaA, analysts share optimism about potential CDMO rebound
Aug 7, 2024 3:13pm
Opdivo-Yervoy, Bavencio fail in head and neck cancer
Sep 20, 2021 7:30am
Pfizer scores FDA nod for Braftovi duo in colon cancer
Apr 9, 2020 11:28am
Array's 'compelling' colon cancer data spark blockbuster talk
May 22, 2019 11:13am
Erbitux woes aside, Merck KGaA cost-cutting lifts Q3 earnings
Nov 15, 2016 9:04am
